[1]
|
Yang, W.Y., Hamilton, J.L., Kopil, C., Beck, J.C. and Tanner, C.M. (2020) Current and Projected Future Economic Burden of Parkinson’s Disease in the U.S. NPJ Parkinson’s Disease, 6, Article No. 15.
https://doi.org/10.1038/s41531-020-0117-1
|
[2]
|
Tysnes, O.B. and Storstein, A. (2017) Epidemiology of Parkin-son’s Disease. Journal of Neural Transmission (Vienna), 124, 901-905. https://doi.org/10.1007/s00702-017-1686-y
|
[3]
|
Pajares, M., Rojo, A.I., et al. (2020) Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications. Cells, 9, Article No. 1687. https://doi.org/10.3390/cells9071687
|
[4]
|
Balestrino, R. and Schapira, A.H.V. (2019) Parkinson Disease. Europe-an Journal of Neurology, 27, 27-42.
https://doi.org/10.1111/ene.14108
|
[5]
|
Trist, B.G., Hare, D.J. and Double, K.L. (2019) Oxidative Stress in the Aging Substantia Nigra and the Etiology of Parkinson’s Disease. Aging Cell, 18, e13031. https://doi.org/10.1111/acel.13031
|
[6]
|
Angelova, P.R., Choi, M.L., Choi, M.L., Berezhnov, A.V. and Berezhnov, A.V. (2020) Alpha Synuclein Aggregation Drives Ferroptosis: An Interplay of Iron, Calcium and Lipid Peroxidation. Cell Death and Differentiation, 27, 2781-2796.
https://doi.org/10.1038/s41418-020-0542-z
|
[7]
|
Peña-Bautista, C., Vento, M., Baquero, M. and Cháfer-Pericás, C. (2019) Lipid Peroxidation in Neurodegeneration. Clinicachimica Acta, International Journal of Clinical Chemistry, 497, 178-188.
https://doi.org/10.1016/j.cca.2019.07.037
|
[8]
|
Bjørklund, G., Peana, M., Maes, M., Dadar, M. and Severin, B. (2020) The Glutathione System in Parkinson’s Disease and Its Progression. Neuroscience & Biobehavioral Reviews, 120, 470-478.
https://doi.org/10.1016/j.neubiorev.2020.10.004
|
[9]
|
Wu, Q.P., Wang, L.F. and Zhao, R.Q. (2022) Neglected Vitamin K Deficiency Causing Coagulation Dysfunction in an Older Patient with Pneumonia: A Case Report. BMC Ger-iatrics, 22, Article No. 628.
https://doi.org/10.1186/s12877-022-03327-6
|
[10]
|
Luoqian, J.Y., Yang, W.Y., Ding, X.L., Tuo, Q.-Z. and Xiang, Z. (2022) Ferroptosis Promotes T-Cell Activation-Induced Neurodegeneration in Multiple Sclerosis. Cellular & Molecular Immunology, 19, 913-924.
https://doi.org/10.1038/s41423-022-00883-0
|
[11]
|
Emekli-Alturfan, E. and Alturfan, A. (2022) The Emerging Rela-tionship between Vitamin K and Neurodegenerative Diseases: A Review of Current Evidence. Molecular Biology Reports, 50, 815-828.
https://doi.org/10.1007/s11033-022-07925-w
|
[12]
|
Stockwell, B.R., Friedmann Angeli, J.P., Bayir, H., Bush, A.I. and Conrad, M. (2017) Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and Disease. Cell, 171, 273-285.
https://doi.org/10.1016/j.cell.2017.09.021
|
[13]
|
Ademowo, O.S., Dias, H.K.I., Burton, D.G.A. and Griffiths, H.R. (2017) Lipid (per) Oxidation in Mitochondria: An Emerging Target in the Ageing Process? Biogerontology, 18, 859-879. https://doi.org/10.1007/s10522-017-9710-z
|
[14]
|
Yan, H.-F., Zou, T., Tuo, Q.-Z. and Xu, S. (2021) Ferroptosis: Mechanisms and Links with Diseases. Signal Transduction and Targeted Therapy, 6, Article No. 49. https://doi.org/10.1038/s41392-020-00428-9
|
[15]
|
Singh, A., Kukreti, R., Saso, L., et al. (2019) Oxidative Stress: A Key Modulator in Neurodegenerative Diseases. Molecules (Basel, Switzerland), 24, Article No. 1583. https://doi.org/10.3390/molecules24081583
|
[16]
|
Forcina, G.C. and Dixon, S.J. (2019) GPX4 at the Crossroads of Lipid Homeostasis and Ferroptosis. Proteomics, 19, e1800311. https://doi.org/10.1002/pmic.201800311
|
[17]
|
Thapa, K., Khan, H., Kanojia, N., Singh, T.G. and Kaur, A. (2022) Therapeutic Insights on Ferroptosis in Parkinson’s Disease. European Journal of Pharmacology, 930, Article ID: 175133. https://doi.org/10.1016/j.ejphar.2022.175133
|
[18]
|
Mahoney-Sánchez, L., Bouchaoui, H., Ayton, S., Devos, D. and Duce, J.A. (2020) Ferroptosis and Its Potential Role in the Physiopathology of Parkinson’s Disease. Progress in Neurobiology, 196, Article ID: 101890.
https://doi.org/10.1016/j.pneurobio.2020.101890
|
[19]
|
Dexter, D.T., Wells, F.R., Agid, F., Agid, Y. and Lees, A.J. (1987) Increased Nigral Iron Content in Postmortem Parkinsonian Brain. The Lancet (London, England), 2, 1219-1220. https://doi.org/10.1016/S0140-6736(87)91361-4
|
[20]
|
Hirsch, E.C., Brel, J.P., Galle, P., Javoy-Agid, F. and Agid, Y. (1991) Iron and Aluminum Increase in the Substantia Nigra of Patients with Parkinson’s Disease: An X-Ray Microa-nalysis. Journal of Neurochemistry, 56, 446-451.
https://doi.org/10.1111/j.1471-4159.1991.tb08170.x
|
[21]
|
de Farias, C.C., Maes, M., Bonifácio, K.L., Bortolasci, C.C. and de Souza Nogueira, A. (2016) Highly Specific Changes in Antioxidant Levels and Lipid Peroxidation in Par-kinson’s Disease and Its Progression: Disease and Staging Biomarkers and New Drug Targets. Neuroscience Letters, 617, 66-71. https://doi.org/10.1016/j.neulet.2016.02.011
|
[22]
|
Sofic, E., Lange, K.W., Jellinger, K. and Riederer, P. (1992) Reduced and Oxidized Glutathione in the Substantia Nigra of Patients with Parkinson’s Disease. Neuroscience Letters, 142, 128-130.
https://doi.org/10.1016/0304-3940(92)90355-B
|
[23]
|
Dionísio, P.A., Amaral, J.D. and Rodrigues, C.M.P. (2021) Oxidative Stress and Regulated Cell Death in Parkinson’s Disease. Ageing Research Reviews, 67, Article ID: 101263. https://doi.org/10.1016/j.arr.2021.101263
|
[24]
|
Battino, M., Littarru, G.P., Gorini, A. and Villa, R.F. (1996) Coen-zyme Q, Peroxidation and Cytochrome Oxidase Features after Parkinson’s-Like Disease by MPTP Toxicity in In-tra-Synaptic and Non-Synaptic Mitochondria from Macaca fascicularis Cerebral Cortex and Hippocampus: Action of Dihydroergocriptine. Neurochemical Research, 21, 1505-1514. https://doi.org/10.1007/BF02533098
|
[25]
|
Bersuker, K., Hendricks, J.M., Li, Z.P., Magtanong, L. and Ford, B. (2019) The CoQ Oxidoreductase FSP1 Acts Parallel to GPX4 to Inhibit Ferroptosis. Nature, 575, 688-692. https://doi.org/10.1038/s41586-019-1705-2
|
[26]
|
Guiney, S.J., Adlard, P.A., Bush, A.I., et al. (2021) Ferroptosis and Cell Death Mechanisms in Parkinson’s Disease. Neurochemistry Interna-tional, 104, 34-48. https://doi.org/10.1016/j.neuint.2017.01.004
|
[27]
|
Ohsaki, Y., Shirakawa, H., Miura, A., Gi-riwono, P.E., Sato, S., et al. (2010) Vitamin K Suppresses the Lipopolysaccharide-Induced Expression of Inflammatory Cytokines in Cultured Macrophage-Like Cells via the Inhibition of the Activation of Nuclear Factor κB through the Re-pression of IKKα/β Phosphorylation. The Journal of Nutritional Biochemistry, 21, 1120-1126. https://doi.org/10.1016/j.jnutbio.2009.09.011
|
[28]
|
De Oliveira, L.G., Angelo, Y.D.S., Iglesias, A.H. and Peron, J.P.S. (2021) Association of Serum Vitamin K2 Levels with Parkinson’s Disease: From Basic Case-Control Study to Big Data Mining Analysis. Aging, 12, 16410-16419.
https://doi.org/10.18632/aging.103691
|
[29]
|
Zhang, C., Liu, X.Y., Jin, S.D. and Chen, Y. (2022) Ferroptosis in Cancer Therapy: A Novel Approach to Reversing Drug Resistance. Molecular Cancer, 21, Article No. 47. https://doi.org/10.1186/s12943-022-01530-y
|
[30]
|
Ciulla, M., Marinelli, L., Cacciatore, I. and Stefano, A. (2019) Role of Dietary Supplements in the Management of Parkinson’s Disease. Biomolecules, 9, Article No. 271. https://doi.org/10.3390/biom9070271
|
[31]
|
Merli, G.J. and Fink, J. (2008) Vitamin K and Thrombosis. Vitamins and Hormones, 78, 265-279.
https://doi.org/10.1016/S0083-6729(07)00013-1
|
[32]
|
Sandeep, Sahu, M.R., Rani, L., Kharat, A.S. and Mondal, A.C. (2023) Could Vitamins Have a Positive Impact on the Treatment of Parkinson’s Disease? Brain Sciences, 13, Arti-cle No. 272. https://doi.org/10.3390/brainsci13020272
|
[33]
|
郁晓丹, 虞燕霞, 沈明强. 帕金森病患者血清中维生素K2及其他相关炎症指标变化和危险因素分析[J]. 中国老年学杂志, 2023, 43(5): 1110-1113.
|
[34]
|
Mishima, E., Mishima, E., Ito, J., Wu, Z.J. and Nakamura, T. (2022) A Non-Canonical Vitamin K Cycle Is a Potent Ferroptosis Sup-pressor. Nature, 608, 778-783. https://doi.org/10.1038/s41586-022-05022-3
|
[35]
|
Dowd, P., Ham, S.W., Naga-nathan, S. and Hershline, R. (1995) The Mechanism of Action of Vitamin K. Annual Review of Nutrition, 15, 419-440. https://doi.org/10.1146/annurev.nu.15.070195.002223
|
[36]
|
Sandeep, et al. (2023) Could Vitamins Have a Positive Impact on the Treatment of Parkinson’s Disease? Brain Sciences, 13, Article No. 272. https://doi.org/10.3390/brainsci13020272
|
[37]
|
Lasemi, R., Kundi, M., Moghadam, N.B., Moghadam, N.B. and Moshammer, H. (2018) Vitamin K2 in Multiple Sclerosis Patients. Wiener Klinische Wochenschrift, 130, 307-313. https://doi.org/10.1007/s00508-018-1328-x
|
[38]
|
Booth, S.L., Shea, M.K., Barger, K. and Leurgans, S.E. (2022) Association of Vitamin K with Cognitive Decline and Neuropathology in Community-Dwelling Older Persons. Alz-heimer’s & Dementia (New York, N.Y.), 8, e12255.
https://doi.org/10.1002/trc2.12255
|
[39]
|
Popescu, A. and German, M. (2021) Vitamin K2 Holds Promise for Alz-heimer’s Prevention and Treatment. Nutrients, 13, Article No. 2206. https://doi.org/10.3390/nu13072206
|
[40]
|
Vos, M., Esposito, G., Edirisinghe, J.N., Vilain, S. and Haddad, D.M. (2012) Vitamin K2 Is a Mitochondrial Electron Carrier That Rescues Pink1 Deficiency. Science (New York, N.Y.), 336, 1306-1310.
https://doi.org/10.1126/science.1218632
|
[41]
|
Prasuhn, J., Kasten, M., Vos, M., et al. (2021) The Use of Vitamin K2 in Patients with Parkinson’s Disease and Mitochondrial Dysfunction (PD-K2): A Theranostic Pilot Study in a Place-bo-Controlled Parallel Group Design. Frontiers in Neurology, 11, Article ID: 592104. https://doi.org/10.3389/fneur.2020.592104
|
[42]
|
Yu, Y.-X., Yu, X.-D., Cheng, Q.-Z., Tang, L. and Shen, M.-Q. (2020) The Association of Serum Vitamin K2 Levels with Parkinson’s Disease: From Basic Case-Control Study to Big Data Mining Analysis. Aging, 12, 16410-16419.
https://doi.org/10.18632/aging.103691
|
[43]
|
Piccinini, M., Scandroglio, F., Prioni, S., Buccinnà, B., Loberto, N., Aureli, M., Chigorno, V., Lupino, E., DeMarco, G., Lomartire, A., et al. (2010) Deregulated Sphingolipid Metabolism and Membrane Organization in Neurodegenerative Disorders. Molecular Neurobiology, 41, 314-340. https://doi.org/10.1007/s12035-009-8096-6
|
[44]
|
Olsen, A.S.B. and Færgeman, N.J. (2017) Sphingolipids: Mem-brane Microdomains in Brain Development, Function and Neurological Diseases. Open Biology, 7, Article ID: 170069. https://doi.org/10.1098/rsob.170069
|
[45]
|
Cores, Á., Carmona-Zafra, N., Clerigué, J., Villacampa, M. and Menéndez, J.C. (2023) Quinones as Neuroprotective Agents. Antioxidants (Basel, Switzerland), 12, Article No. 1464. https://doi.org/10.3390/antiox12071464
|
[46]
|
Rocha, E.M., De Miranda, B. and Sanders, L.H. (2017) Al-pha-Synuclein: Pathology, Mitochondrial Dysfunction and Neuroinflammation in Parkinson’s Disease. Neurobiology of Disease, 109, 249-257.
https://doi.org/10.1016/j.nbd.2017.04.004
|
[47]
|
da Silva, F.L., Coelho Cerqueira, E., de Freitas, M.S., Gonçalves, D.L. and Costa, L.T. (2012) Vitamins K Interact with N-Terminus α-Synuclein and Modulate the Protein Fibrillization in Vitro. Exploring the Interaction between Quinones and α-Synuclein. Neurochemistry International, 62, 103-112. https://doi.org/10.1016/j.neuint.2012.10.001
|
[48]
|
Ferland, G. (2012) Vitamin K, an Emerging Nutrient in Brain Function. Biofactors, 38, 151-157.
https://doi.org/10.1002/biof.1004
|
[49]
|
Gao, F., Chen, D., Hu, Q. and Wang, G. (2013) Rotenone Directly Induces BV2 Cell Activation via the p38 MAPK Pathway. PLOS ONE, 8, e72046. https://doi.org/10.1371/journal.pone.0072046
|